Navigation Links
Arteriocyte Receives FDA Approval to Move Forward with Critical Limb Ischemia Trial
Date:1/28/2011

CLEVELAND, Jan. 28, 2011 /PRNewswire-USNewswire/ -- Arteriocyte®, a leading clinical stage biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts that develops proprietary stem cell and tissue engineering based therapies, announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan MAR01™ technology in the treatment of Critical Limb Ischemia (CLI). The FDA Investigational Device Exemption (IDE 14522) allows Arteriocyte and its clinical partners to initiate evaluation of concentrated marrow injections (using the Magellan MAR01™ technology) in improving perfusion in ischemic tissue in affected limbs of patients with CLI who are not eligible for revascularization surgery.

(Logo: http://photos.prnewswire.com/prnh/20100624/ALOGO)

The Magellan technology combines a rapid bedside tissue concentration device and sterile surgical disposables that produce platelet rich plasma from blood and bone marrow aspirations in approximately 15 minutes and was FDA approved through the 510(k) process for use as deemed appropriate by surgeons. The Magellan MAR01™ technology enables the rapid "closed system" concentration of aspirated bone marrow, yielding an injectable tissue rich in platelets, hematopoietic stem cells and mesenchymal stem cells, commonly viewed as key components in tissue repair. The company is developing MAR01™ for use as a clinical treatment for Critical Limb Ischemia, and plans to initiate additional clinical trials evaluating MAR01™ in cardiovascular disease, and the clinical setting of orthopedics and tissue repair during 2011.

Patient enrollment for the phase I safety study will begin immediately at The Ohio State University Medical Center (as the first clinical site), under the direction of Dr. Michael Go, Assistant Professor of Surgery in the Division
'/>"/>

SOURCE Arteriocyte, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arteriocyte Named Top Biotech Start Up Venture by the Ohio Venture Association for 2010
2. 3SBio Inc. Receives SFDA Approval for TPIAO Label Extension for the Treatment of ITP
3. Soligenix Receives FDA Orphan Drug Designation for RiVax™ for the Prevention of Ricin Intoxication
4. Regenicin Receives Positive Feedback at OneMedForum Conference
5. Neogens Rapid Test for Salmonella enteritidis Receives FDA Approval
6. Regenicin COO Receives Citizenship Award from VFW Post 1 in Colorado
7. Foundation Venture Capital Group Company Receives $8.2 Million DoD Contract
8. Teysuno™ (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer
9. Quest Diagnostics® Care360™ EHR Receives ONC-ATCB 2011/2012 Certification
10. Pittsburgh-based BIOSAFE Receives EPA Registration and Enters Into Commercialization Agreement with Union Springs Pharmaceuticals
11. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... June 30, 2015  The University of California, ... (CCE/Bio) and UC San Diego Extension announced their ... held Aug.  12 – 14, 2015, at UC ... workshop provides an intense exposure to best practices ... is well-suited to biologists, process engineers and business ...
(Date:6/30/2015)... June 30, 2015 /PRNewswire/ - RepliCel Life Sciences ... regenerative medicine company focused on the development of ... in its Phase 1/2 clinical trial of RCT-01, ... Achilles tendinosis, has been enrolled and their tissue ... injections. RCT-01 is comprised of non-bulbar dermal sheath ...
(Date:6/30/2015)... ... June 30, 2015 , ... Southern ... accepted the position of vice president of instruction at Chippewa Valley Technical College ... greatly appreciated the opportunity to lead SIUE during the past three years,” Furst-Bowe ...
(Date:6/30/2015)... ... June 30, 2015 , ... Cannavoices , ... an unprecedented digital video and broadcast initiative. Produced by filmmakers, the multi-platform initiative ... of legal medical cannabis stories ever assembled. , Cannavoices profiles Advocates, Patients, ...
Breaking Biology Technology:UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 3Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3
... Omthera Pharmaceuticals, Inc., a privately-held emerging ... of a randomized, open-label, four-way cross-over pharmacokinetics ... Omthera,s lead compound for the treatment of ... the leading prescription Omega-3.  Epanova is an ...
... Nov. 8, 2010 Solutia Inc. (NYSE: ... sold its Perkalink® business and entered into a ... to LANXESS, a Germany-based specialty chemicals company.   ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081029/AQW096LOGO) "The sale ...
... in Europe Could Be Prevented -- PRAGUE, November 8, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
Cached Biology Technology:Omthera Pharmaceuticals, Inc. Announces Initiation of the ECLIPSE Trial: Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation 2Omthera Pharmaceuticals, Inc. Announces Initiation of the ECLIPSE Trial: Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation 3Solutia Announces Sale of Perkalink® Business and Select Primary Accelerators Assets 2Solutia Announces Sale of Perkalink® Business and Select Primary Accelerators Assets 3Study Shows Cardiovascular Deaths in Europe Could Be Prevented 2Study Shows Cardiovascular Deaths in Europe Could Be Prevented 3Study Shows Cardiovascular Deaths in Europe Could Be Prevented 4Study Shows Cardiovascular Deaths in Europe Could Be Prevented 5Study Shows Cardiovascular Deaths in Europe Could Be Prevented 6Study Shows Cardiovascular Deaths in Europe Could Be Prevented 7Study Shows Cardiovascular Deaths in Europe Could Be Prevented 8Study Shows Cardiovascular Deaths in Europe Could Be Prevented 9Study Shows Cardiovascular Deaths in Europe Could Be Prevented 10
(Date:6/9/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, will be providing demonstrations of its ... 2015 Drug Information Association (DIA) Annual Meeting in ... presentations will include previews of many exciting new enhancements ... iMedNet 2015 Feature 1 Release. ...
(Date:6/8/2015)... , June 8, 2015  Trovagene, Inc. (NASDAQ: ... that clinical data featuring its Precision Cancer Monitoring SM ... and Liquid Biopsies conference in San Diego, CA ... AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy ... on June 13-16. "We continue to advance ...
(Date:6/5/2015)... GERMANTOWN, Md. , June 5, 2015  Intrexon ... synthetic biology, today announced that it has determined the ... of all of its 17,830,305 shares of ZIOPHARM Oncology, ... or about June 12, 2015, the distribution date, as ... stock, and on warrants to purchase shares of Intrexon ...
Breaking Biology News(10 mins):MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 2Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 4Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 2Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 3Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 4
... and lifestyle offers significant benefits to people with chronic ... Dietitian Katrina Campbell, who graduated with her PhD ... at the Royal Brisbane and Women,s Hospital (RB&WH) and ... thesis. Dr Campbell said depending on the patient,s ...
... to manage some of Florida,s most popular sport fish, ... Effective Strategies for the Management of Sustainable Fisheries: Biology ... Ault, an assistant professor in the Division of ... has a unique high-tech tagging approach to studying tarpon ...
... PatientSecure(TM) on Display at Leading Healthcare Conference, ... 20 Identity,management in a busy healthcare ... especially when it must be repeated with ... Inc., a leading supplier of,innovative computer products, ...
Cached Biology News:Diet support helps chronic kidney patients 2New tarpon, bonefish compendium published 2Fujitsu and HT Systems Partner to Provide Biometric Patient Identity Management 2Fujitsu and HT Systems Partner to Provide Biometric Patient Identity Management 3Fujitsu and HT Systems Partner to Provide Biometric Patient Identity Management 4
... peptide derived from the internal region of ... Specific for the internal region of the ... the target band at ~590 kDa. ... media from primary tracheobranchial epithelial cultures and ...
Gloves are 9.25 long, latex, powder free, smooth and ambidextrous....
Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
Request Info...
Biology Products: